Long-term Risk of Colorectal Cancer After Removal of Conventional Adenomas and Serrated Polyps
- PMID: 31302144
- PMCID: PMC6954345
- DOI: 10.1053/j.gastro.2019.06.039
Long-term Risk of Colorectal Cancer After Removal of Conventional Adenomas and Serrated Polyps
Abstract
Background & aims: Endoscopic screening reduces incidence and mortality of colorectal cancer (CRC) because precursor lesions, such as conventional adenomas or serrated polyps, are removed. Individuals with polypectomies are advised to undergo colonoscopy surveillance to prevent CRC. However, guidelines for surveillance intervals after diagnosis of a precursor lesion, particularly for individuals with serrated polyps, vary widely, and lack sufficient supporting evidence. Consequently, some high-risk patients do not receive enough surveillance and lower-risk subjects receive excessive surveillance.
Methods: We examined the association between findings from first endoscopy and CRC risk among 122,899 participants who underwent flexible sigmoidoscopy or colonoscopy in the Nurses' Health Study 1 (1990-2012), Nurses' Health Study 2 (1989-2013), or the Health Professionals Follow-up Study (1990-2012). Endoscopic findings were categorized as no polyp, conventional adenoma, or serrated polyp (hyperplastic polyp, traditional serrated adenoma, or sessile serrated adenoma, with or without cytological dysplasia). Conventional adenomas were classified as advanced (≥10 mm, high-grade dysplasia, or tubulovillous or villous histology) or nonadvanced, and serrated polyps were assigned to categories of large (≥10 mm) or small (<10 mm). We used a Cox proportional hazards regression model to calculate the hazard ratios (HRs) of CRC incidence, after adjusting for various potential risk factors.
Results: After a median follow-up period of 10 years, we documented 491 incident cases of CRC: 51 occurred in 6161 participants with conventional adenomas, 24 in 5918 participants with serrated polyps, and 427 in 112,107 participants with no polyp. Compared with participants with no polyp detected during initial endoscopy, the multivariable HR for incident CRC in individuals with an advanced adenoma was 4.07 (95% confidence interval [CI] 2.89-5.72) and the HR for CRC in individuals with a large serrated polyp was 3.35 (95% CI 1.37-8.15). In contrast, there was no significant increase in risk of CRC in patients with nonadvanced adenomas (HR 1.21; 95% CI 0.68-2.16, P = .52) or small serrated polyps (HR 1.25; 95% CI 0.76-2.08; P = .38).
Conclusions: These findings provide support for guidelines that recommend repeat lower endoscopy within 3 years of a diagnosis of advanced adenoma and large serrated polyps. In contrast, patients with nonadvanced adenoma or small serrated polyps may not require more intensive surveillance than patients without polyps.
Keywords: early detection; interval cancer; polypectomy; secondary prevention.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Figures
Comment in
-
Surveillance Colonoscopy: Time to Dial it Back?Gastroenterology. 2020 Mar;158(4):816-817. doi: 10.1053/j.gastro.2020.01.010. Epub 2020 Jan 10. Gastroenterology. 2020. PMID: 31930987 No abstract available.
Similar articles
-
Risk of colorectal cancer incidence and mortality after polypectomy: a Swedish record-linkage study.Lancet Gastroenterol Hepatol. 2020 Jun;5(6):537-547. doi: 10.1016/S2468-1253(20)30009-1. Epub 2020 Mar 17. Lancet Gastroenterol Hepatol. 2020. PMID: 32192628 Free PMC article.
-
Long-term risk of colorectal cancer in individuals with serrated polyps.Gut. 2015 Jun;64(6):929-36. doi: 10.1136/gutjnl-2014-307793. Epub 2014 Nov 16. Gut. 2015. PMID: 25399542 Clinical Trial.
-
Increased Risk of Colorectal Cancer in Individuals With a History of Serrated Polyps.Gastroenterology. 2020 Aug;159(2):502-511.e2. doi: 10.1053/j.gastro.2020.04.004. Epub 2020 Apr 8. Gastroenterology. 2020. PMID: 32277950
-
Colorectal Cancer Screening for the Serrated Pathway.Gastrointest Endosc Clin N Am. 2020 Jul;30(3):457-478. doi: 10.1016/j.giec.2020.02.007. Epub 2020 Apr 8. Gastrointest Endosc Clin N Am. 2020. PMID: 32439082 Review.
-
Risk factors for metachronous colorectal cancer or advanced lesions after endoscopic resection of serrated polyps: a systematic review and meta-analysis.Gastrointest Endosc. 2024 Oct;100(4):605-615.e14. doi: 10.1016/j.gie.2024.05.021. Epub 2024 Jun 6. Gastrointest Endosc. 2024. PMID: 38851458 Review.
Cited by
-
Stool and blood biomarkers for colorectal cancer management: an update on screening and disease monitoring.Mol Cancer. 2024 Nov 19;23(1):259. doi: 10.1186/s12943-024-02174-w. Mol Cancer. 2024. PMID: 39558327 Free PMC article. Review.
-
Enhancing colorectal cancer screening in high-risk population through fecal immunochemical test surveillance: Results from a surveillance program.Cancer Med. 2024 Oct;13(20):e70145. doi: 10.1002/cam4.70145. Cancer Med. 2024. PMID: 39428708 Free PMC article.
-
Prediction of metachronous advanced colorectal neoplasia by KRAS mutation in polyps.United European Gastroenterol J. 2024 Nov;12(9):1179-1189. doi: 10.1002/ueg2.12667. Epub 2024 Oct 13. United European Gastroenterol J. 2024. PMID: 39400528 Free PMC article.
-
Post-polypectomy surveillance: follow-up recommendations from the Alberta Colorectal Cancer Screening Program.J Can Assoc Gastroenterol. 2024 Mar 19;7(4):319-328. doi: 10.1093/jcag/gwae007. eCollection 2024 Aug. J Can Assoc Gastroenterol. 2024. PMID: 39139219 Free PMC article.
-
Morphology, Histopathology, and Anatomical Distribution of Sporadic Colorectal Polyps in Chinese Patients.Gastro Hep Adv. 2023 Jun 12;2(7):964-970. doi: 10.1016/j.gastha.2023.06.002. eCollection 2023. Gastro Hep Adv. 2023. PMID: 39130775 Free PMC article.
References
-
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. - PubMed
Publication types
MeSH terms
Grants and funding
- R35 CA197735/CA/NCI NIH HHS/United States
- P30 DK043351/DK/NIDDK NIH HHS/United States
- R01 CA202704/CA/NCI NIH HHS/United States
- K24 DK098311/DK/NIDDK NIH HHS/United States
- UM1 CA186107/CA/NCI NIH HHS/United States
- R03 CA197879/CA/NCI NIH HHS/United States
- R35 CA253185/CA/NCI NIH HHS/United States
- P50 CA127003/CA/NCI NIH HHS/United States
- R21 CA230873/CA/NCI NIH HHS/United States
- P01 CA087969/CA/NCI NIH HHS/United States
- P01 CA055075/CA/NCI NIH HHS/United States
- R01 CA151993/CA/NCI NIH HHS/United States
- U01 CA176726/CA/NCI NIH HHS/United States
- U01 CA167552/CA/NCI NIH HHS/United States
- L30 CA209764/CA/NCI NIH HHS/United States
- R01 CA137178/CA/NCI NIH HHS/United States
- R01 CA176272/CA/NCI NIH HHS/United States
- T32 CA009001/CA/NCI NIH HHS/United States
- UM1 CA167552/CA/NCI NIH HHS/United States
- K99 CA215314/CA/NCI NIH HHS/United States
- R00 CA215314/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
